OR WAIT null SECS
September 03, 2021
The intranasal route of administration is showing clinical promise, particularly for COVID-19, but there are multiple hurdles to overcome to ensure successful formulation.
August 27, 2021
FDA granted orphan drug designation for imatinib in AER-901 for the treatment of patients with pulmonary arterial hypertension.
August 01, 2021
The choice of delivery platform for inhaled drug products is contingent on API-related factors, as well as the development stage of the product.
July 03, 2021
Particle performance in a DPI can be optimized by fine-tuning the formulation and manufacturing process parameters.
June 03, 2021
Particle engineering is a vital tool in overcoming many formulation challenges, and technological advances are enabling developers to achieve the full potential of pipeline molecules.
September 14, 2020
Vectura will support the product from Phase I through to commercial launch.
September 02, 2020
Creating an inhaled formulation is one way in which improved efficacy or added value can be achieved in projects to repurpose or reposition existing drugs.
September 01, 2020
The Ventofor Combi Fix will be brought into the Turkish market via Bilim’s development program, while the PowdAir Plus DPI is manufactured and commercialized by H&T Presspart under a patent license from Hovione.
August 03, 2020
Particle engineering is a useful tool to manipulate API particles into a form that is manufacturable and deliverable to the patient.
May 04, 2020
Kindeva Drug Delivery plans capital investment and jobs growth.